代谢组学评价方法在支气管哮喘研究中的应用进展

Application progress of metabonomics evaluation methods in bronchial asthma

支气管哮喘(哮喘)是一种复杂的异质性疾病,其漏诊率、误诊率极高,且反复发作可引起慢性阻塞性肺疾病、肺气肿、肺源性心脏病等并发症。近年来,基于质谱技术的代谢组学快速发展,它能敏感地捕捉哮喘患者体内的代谢波动和病理改变,通过对体内各种代谢路径的底物和产物的小分子代谢物进行分析,寻找疾病的生物标志物,为哮喘的早期诊断和严重程度评估提供一种较好的方法。通过查阅国内外相关文献,分析归纳代谢组学技术在哮喘发病机制、早期诊断及严重程度评估方面的研究进展,以期为哮喘的研究提供参考。

Bronchial asthma(asthma)is a complex heterogeneous disease,with a high rate of missed diagnosis and misdiagnosis.Repeated attacks of bronchial asthma can cause complications such as chronic obstructive pulmonary disease,emphysema,and pulmonary heart disease.In recent years,mass-spectrometry-based metabolomics has developed rapidly.It can sensitively identify metabolic fluctuations and pathological changes in patients with asthma.By analyzing the molecules produced by various metabolic pathways,it can help us to find relevant biomarkers and provide a better method for early diagnosis and severity assessment of asthma.We reviewed and analyzed the literature of metabolomics technology in disease progression,early diagnosis and severity assessment,so as to provide reference for asthma research.